Research Report:meningococcal vaccines - italy drug forecast and market analysis to 2022
Upcoming SlideShare
Loading in...5
×
 

Research Report:meningococcal vaccines - italy drug forecast and market analysis to 2022

on

  • 372 views

...



PharmaPoint: Meningococcal Vaccines - Italy Drug Forecast and Market Analysis to 2022SummaryGlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines - Italy Drug Forecast and Market Analysis to 2022.
To Read The Complete Report Kindly Visit: http://www.marketresearchreports.biz/analysis/170314
For All Latest Reports Kindly visit: http://www.marketresearchreports.biz


Statistics

Views

Total Views
372
Views on SlideShare
372
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Research Report:meningococcal vaccines - italy drug forecast and market analysis to 2022 Research Report:meningococcal vaccines - italy drug forecast and market analysis to 2022 Document Transcript

  • PharmaPoint: Meningococcal Vaccines - Italy Drug Forecast and Market Analysis to 2022 GlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines Italy Drug Forecast and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022. Total sales in this segment of the market will decline slightly due to a population decrease in the targeted age group of 1224 months of age. GlobalData predicts that relative patient share for the three MenC conjugate vaccines will remain unchanged for the duration of the forecast period because Nuron Biotechs Meningitec, Novartis Menjugate, and Baxters NeisVac-C possess nearly identical clinical profiles and price points. The MenC conjugate patient share is largely determined by prescriber preference in Italy and therefore is not expected to change drastically during the forecast period. Scope Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on the key drugs in Italy including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for the top drugs in Italy from 2012-2022. Analysis of the impact of key events as well the drivers and restraints affecting Italy Meningococcal Vaccines market. Reasons to buy Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and in-depth analysis of drug performance Obtain sales forecast for drugs from 2012-2022 in Italy table Of Contents 1 Table Of Contents 1 1.1 List Of Tables 3 1.2 List Of Figures 3 2 Executve Summary 4 2.1 Sales For Meningococcal Vaccine In Italy 4 2.2 What Do The Physicians Think? 5 PharmaPoint: Meningococcal Vaccines - Italy Drug Forecast and Market Analysis to 2022
  • 3 Introduction 6 3.1 Catalyst 6 3.2 Related Reports 7 3.3 Upcoming Related Reports 9 4 Disease Overview 9 4.1 Etiology And Pathophysiology 10 4.1.1 Etiology 10 4.1.2 Pathophysiology 11 4.2 Symptoms 12 4.3 Prognosis 13 5 Disease Management 13 5.1 Meningococcal Immunization Policy 14 5.2 Italy 15 5.2.1 Meningococcal Immunization Recommendations And Policies 15 5.2.2 Clinical Practice 16 6 Competitive Assessment 16 6.1 Overview 16 6.2 Strategic Competitor Assessment 16 6.3 Product Profiles Major Brands 18 6.3.1 Menveo 18 6.3.2 Nimenrix 22 6.3.3 Meningitec 24 6.3.4 Menjugate 26 6.3.5 Neisvac-c 28 6.3.6 Bexsero 31 7 Opportunity And Unmet Need 33 7.1 Overview 33 7.2 Unmet Needs 34 7.2.1 Unmet Need: Protection Against Serogroup B Disease 34 7.2.2 Unmet Need: A Pentavalent (menabcwy) Vaccine 34 7.2.3 Unmet Need: More Cost-effective Vaccines 35 7.2.4 Unmet Need: Improved Duration Of Immunity In Children And Adolescents 36 7.2.5 Unmet Need: Immunogenic Infant Vaccines 37 7.2.6 Unmet Need: Improved Vaccination Coverage Rates 38 7.2.7 Unmet Need: Increased Patient Awareness And Education 39 7.3 Unmet Needs Gap Analysis 40 7.4 Opportunities 41 7.4.1 Opportunity: Broadening Serogroup Protection With New And Existing Antigen Combinations 41 7.4.2 Opportunity: Improving Immune Response Duration With Adjuvants 42 PharmaPoint: Meningococcal Vaccines - Italy Drug Forecast and Market Analysis to 2022
  • 7.4.3 Opportunity: Developing More Cost-effective Vaccines By Partnering With Manufacturers In Emerging Markets 43 8 Pipeline Assessment 43 8.1 Overview 43 8.2 Promising Vaccines In Clinical Development 43 8.2.1 Mnb Rlp2086 47 8.3 Promising Vaccines In Early Clinical Development 51 8.3.1 Meninge Acyw Conj. 51 8.3.2 Menabcwy 55 8.3.3 Menc Conjugate 57 8.3.4 Heptavalent Dtp-hib-hepb-ipv-menc 60 9 Market Outlook 62 9.1 Italy 62 9.1.1 Forecast 62 9.1.2 Key Events 65 9.1.3 Drivers And Barriers 66 10 Appendix 68 10.1 Bibliography 68 10.2 Abbreviations 78 10.3 Methodology 81 10.4 Forecasting Methodology 81 10.4.1 Vaccine Coverage 82 10.4.2 Vaccine Approval Vs. Routine Schedule Inclusion 82 10.4.3 Vaccines Included 83 10.4.4 Key Launch Dates 84 10.4.5 General Pricing Assumptions 85 10.4.6 Individual Vaccine Assumptions 86 10.4.7 Pricing Of Pipeline Agents 91 10.5 Physicians And Specialists Included In This Study 92 10.6 About The Authors 95 10.6.1 Authors 95 10.6.2 Reviewers 95 10.6.3 Global Head Of Healthcare 95 10.7 About Globaldata 96 10.8 Contact Us 96 10.9 Disclaimer 96 Market Research Report(http://www.marketresearchreports.biz/) Marketresearchreports.biz is the most comprehensive collection of market research reports. Marketresearchreports.biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. PharmaPoint: Meningococcal Vaccines - Italy Drug Forecast and Market Analysis to 2022
  • We serve all sizes and types of companies spanning across various industries. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.com Website: www.marketresearchreports.biz PharmaPoint: Meningococcal Vaccines - Italy Drug Forecast and Market Analysis to 2022